Your browser doesn't support javascript.
loading
Harnessing the Power of Mucosal-Associated Invariant T (MAIT) Cells in Cancer Cell Therapy.
Sugimoto, Chie; Fujita, Hiroyoshi; Wakao, Hiroshi.
Affiliation
  • Sugimoto C; Host Defense Division, Center for Frontier Medicines, Dokkyo Medical University, Mibu 321-0293, Japan.
  • Fujita H; Host Defense Division, Center for Frontier Medicines, Dokkyo Medical University, Mibu 321-0293, Japan.
  • Wakao H; Host Defense Division, Center for Frontier Medicines, Dokkyo Medical University, Mibu 321-0293, Japan.
Biomedicines ; 10(12)2022 Dec 07.
Article de En | MEDLINE | ID: mdl-36551916
ABSTRACT
Mucosal-associated invariant T (MAIT) cells, a burgeoning type of the innate-like T cells, play a crucial role in maintaining immune homeostasis, particularly in host defense. Although many studies have implied the use of MAIT cells in tumor immunity, whether MAIT cells are pro-tumor or anti-tumor has remained elusive, as in the case for other innate-like T cells that possess dichotomous roles in tumor immunity. Although this difficulty persists where endogenous MAIT cells are the target for therapeutic intervention, the advent of induced pluripotent stem-cell-derived MAIT cells (reMAIT cells) will make it possible to harness these cells for immune cell therapy. In this review, we will discuss possible roles of MAIT cells in tumor immunity and the potential of reMAIT cells to treat tumors.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Risk_factors_studies Langue: En Journal: Biomedicines Année: 2022 Type de document: Article Pays d'affiliation: Japon

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Risk_factors_studies Langue: En Journal: Biomedicines Année: 2022 Type de document: Article Pays d'affiliation: Japon